Publications

  1. Wu Y, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin S, Cheng A, Kunju LP, Siddiqui J, Tomlins SA, Wyngaard P, Sadis S, Roychowdhury S, Hussain M, Feng FY, Zalupski MM, Talpaz M, Pienta KJ, Rhodes DR, Robinson DR and Chinnaiyan, AM.  Identification of Targetable FGFR Gene Fusions in Diverse Cancers.  Cancer Discovery, Epub 2013 April 4.  PMID 23558953
  2. Simon, Richard, Roychowdhury S. Implementing Personalized Cancer Genomics in Clinical Trials. Nature Reviews in Drug Discovery, May, 2013, Vol. 12, No. 5, Pages 358-369.
  3. Roychowdhury, S, Chinnaiyan AM. Advancing Precision Medicine for Prostate Cancer through Genomics. Journal of Clinical Oncology, 2013, April 15.
  4. Robinson DR, Wu Y, Kalyana-Sundaram S, Cao X, Lonigro R, Sung Y, Chen C, Zhang L, Wang R, Su F, Iyer MK, Roychowdhury S, Siddiqui J, Pienta, K, Kunju LP, Talpaz M, Mosquera J, Singer S, Schuetze S, Antonescu, CR, Chinnaiyan AM. Identification of Recurrent NAB2-STAT6 Gene Fusions in Solitary Fibrous Tumor / Hemangiopericytoma by Clinical Sequencing, Nature Genetics, Feb. 2013, Vol. 45, No. 2, Pages 180-185.
  5. Roychowdhury S. Cancer Genomics Meets Clinical Trials: the Challenge Ahead. Personalized Medicine, July 2012, Vol. 9, No. 5, Pages 459-461.
  6. Roychowdhury S, Iyer MK, Robinson D, Lonigro R, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist M, Barrette T, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis C, Innis JK, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM. Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study, Science Translational Medicine. 2011 Nov 30;3(111):111ra121.
  7. Roychowdhury S, Talpaz M. Managing Resistance in Chronic Myeloid Leukemia, Blood Reviews, Blood Rev. 2011 Oct 6, Nov;25(6):279-90.
  8. Blaser BW, Schwind NR, Karol S, Chang D, Shin S, Roychowdhury S, Becknell B, Ferketich AK, Kusewitt DF, Blazar BR, Caligiuri MA. Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity. Blood. 2006 Oct 1;108(7):2463-9.
  9. Roychowdhury S, Blaser BW, Freud AG, Katz K, Bhatt D, Ferketich AK, Bergdall V, Kusewitt D, Baiocchi RA, Caligiuri MA. IL-15 but not IL-2 Rapidly Induces Lethal Xenogeneic Graft Versus Host Disease. Blood. 2005. Oct 1;106(7):2433-5.
  10. Freud, AG, Becknell, B, Roychowdhury S, Mao, HC, Hughes, TL, Marburger, TB, Baiocchi, RA, Guimond, M, Caligiuri, MA.  A novel human CD34(+) subset that constitutively expresses the high affinity interleukin-2 receptor traffics to lymph nodes and differentiates into CD56bright natural killer cells. Immunity. 2005. Mar;22(3):295-304 .
  11. Roychowdhury S, May KF, Tzou KS, Lin T, Bhatt D, Freud AG, Guimond M, Ferketich AK, Liu Y, Caligiuri MA.  Failed adoptive immunotherapy with tumor specific T cells: reversal with low dose IL-15 but not low dose IL-2. Cancer Res. 2004. Nov; 64(21):8062-67.
  12. Dierksheide JE, Baiocchi RA, Ferketich AK, Roychowdhury S, Pelletier RP, Eisenbeis CF, Caligiuri MA, Vanbuskirk AM. IFN-gamma gene polymorphisms associate with development of EBV-positive Lymphoproliferative Disease in hu PBL SCID mice. Blood. 2004 Feb 15;105(4):1558-1565.
  13. May KF, Roychowdhury S, Bhatt D, Kocak E, Bai XF, Liu JQ, Ferketich AK, Martin EW, Caligiuri MA, Zheng P, Liu Y. Anti-human CTLA-4 monoclonal antibody promotes T cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies. Blood. 2004 Feb 1;105(3):1114-1120.
  14. Roychowdhury S, Baiocchi RA, Vourganti S, Bhatt D, Blaser BW, Freud AG, Chou J, Chen CS, Xiao JJ, Parthun M, Chan KK, Eisenbeis CF, Ferketich AK, Grever MR, Chen CS, Caligiuri MA. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus positive lymphoproliferative disorder. J Natl Cancer Inst. 2004 Oct 6;96(19):1447-57
  15. Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, Kelbick N, Stephens J, Byrd JC, Grever MR, Caligiuri MA, Porcu P. Combination immunotherapy of B-cell non Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clin Cancer Res. 2004 Sep 15;10(18 Pt I):6101-10.
  16. Blaser BW*, Roychowdhury S*, Kim DJ, Schwind NR, Bhatt D, Yuan W, Kusewitt DF, Ferketich AK, Caligiuri MA, Guimond M. Donor Derived IL-15 is Critical for Acute Allogeneic Graft-Versus-Host Disease. Blood. 2004 Jan 15;105(2):894-901.  *Blaser and Roychowdhury contributed equally to this work.
  17. Roychowdhury S, Peng R, Baiocchi RA, Bhatt D, Vourganti S, Grecula J, Gupta N, Eisenbeis CF, Nuovo GJ, Yang W, Schmalbrock P, Ferketich A, Moeschberger M, Porcu P, Barth RF, Caligiuri MA. Experimental treatment of Epstein-Barr virus associated primary central nervous system lymphoma. Cancer Res. 2003 Mar 1;63(5):965-71.
  18. Porcu P, Eisenbeis CF, Pelletier RP, Davies EA, Baiocchi RA, Roychowdhury S, Vourganti S, Nuovo GJ, Marsh WL, Ferketich AK, Henry ML, Ferguson RM, Caligiuri MA. Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration. Blood. 2002 Oct 1;100(7):2341-8.
  19. Baiocchi RA, Ward JS, Carrodeguas L, Eisenbeis CF, Peng R, Roychowdhury S, Vourganti S, Sekula T, O'Brien M, Moeschberger M, Caligiuri MA. GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder. J Clin Invest. 2001 Sep;108(6):887-94.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu